CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that John P. Butler, President and Chief Executive Officer,
will present at the 16th Annual Needham Healthcare Conference
on Tuesday, April 4, 2017, at 10:00 a.m. Eastern Time. The conference is
being held at the Westin NY Grand Central Hotel in New York City.
A live audio webcast of the presentation will be available on the
company's website at http://ir.akebia.com/events.cfm.
Archived presentations will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia's lead product candidate, vadadustat, is an
investigational oral therapy in development for the treatment of anemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia's global Phase 3 program for vadadustat, which includes
the PRO2TECT studies for non-dialysis patients with anemia
secondary to chronic kidney disease and the INNO2VATE studies
for dialysis-dependent patients, is currently ongoing. For more
information, please visit our website at www.akebia.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170329006005/en/
Theresa McNeely, 617-844-6113
and Investor Relations
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media